Several analysts have recently updated their ratings and price targets for Sarepta Therapeutics (NASDAQ: SRPT):

  • 12/27/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $76.00 price target on the stock.
  • 12/27/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at UBS Group AG. They now have a $56.51 price target on the stock, down previously from $76.00.
  • 12/25/2017 – Sarepta Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/19/2017 – Sarepta Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 12/15/2017 – Sarepta Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Sarepta's Exondys 51 is the first DMD treatment to gain approval in the United States. Also, a potential marketing approval in the EU should further boost sales.The company is also focused on reimbursement programs. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, is a concern. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. The company’s shares have outperformed the industry so far this year.”
  • 12/1/2017 – Sarepta Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $75.00 price target on the stock.
  • 10/30/2017 – Sarepta Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $54.00 price target on the stock. According to Zacks, “Sarepta beat estimates for both earnings and sales in the third quarter and raised its 2017 sales outlook. Exondys 51 is the first DMD treatment to gain approval in the United States. Also, a potential marketing approval in the EU should further boost sales.The company is also focused on reimbursement programs. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, is a concern. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. The company’s shares have outperformed the industry so far this year.”

Shares of Sarepta Therapeutics Inc (SRPT) traded down $0.14 during midday trading on Friday, reaching $56.61. The company had a trading volume of 753,800 shares, compared to its average volume of 2,233,659. The stock has a market capitalization of $3,667.87, a price-to-earnings ratio of -27.61 and a beta of 1.39. Sarepta Therapeutics Inc has a 52-week low of $26.26 and a 52-week high of $57.57. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. The firm had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter in the prior year, the firm earned ($0.95) earnings per share. sell-side analysts anticipate that Sarepta Therapeutics Inc will post -3.11 earnings per share for the current year.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 11,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total value of $575,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now directly owns 13,333 shares of the company’s stock, valued at $745,181.37. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,167 shares of company stock worth $1,497,619. 9.60% of the stock is owned by insiders.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.